Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | TACR1 | P25103 | 3/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | AGXT | P21549 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5221460 | 0.98 | KDM4E (0.59) | KDM4EPOLBTSHRSLC6A2TAAR1 | |
| SCHEMBL5390546 | 0.98 | KDM4E (0.59) | KDM4EPOLBTSHRSLC6A2TAAR1 | |
| Hydrochloric Acid SCHEMBL5221456 | 0.96 | KDM4E (0.58) | KDM4EPOLBTSHRSLC6A2TAAR1 | |
| SCHEMBL29108931 | 0.88 | KDM4E (0.61) | KDM4EPOLBTSHRSLC6A2TAAR1 | |
| SCHEMBL14304175 | 0.85 | KDM4E (0.54) | KDM4EPOLBTSHRSLC6A2TAAR1 | |
| SCHEMBL21408338 | 0.83 | KDM4E (0.78) | KDM4EPOLBTSHRSLC6A2TAAR1 | |
| SCHEMBL1691827 | 0.83 | TSHR (0.61) | KDM4EPOLBTSHRSLC6A2TAAR1 | |
| SCHEMBL15663590 | 0.82 | KDM4E (0.56) | KDM4EPOLBTSHRSLC6A2TAAR1 | |
| SCHEMBL6043011 | 0.81 | TSHR (0.58) | KDM4EPOLBTSHRSLC6A2TAAR1 | |
| SCHEMBL1927581 | 0.80 | IDO1 (0.50) | KDM4EPOLBTAAR1TACR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-01-14 | — | — | US | disclosed |
| CN-111527090-B | Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors | 拜耳公司 | 2023-05-26 | — | — | CN | disclosed |
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2023-01-05 | — | — | US | disclosed |
| CN-109863160-B | Nucleoside phosphate compound and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| US-11319324-B2 | Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-03 | — | — | US | disclosed |
| US-11319324-B2 | Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-03 | — | — | US | disclosed |
| EP-3700907-B1 | NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS | BAYER AG (DE) | 2022-03-09 | — | — | EP | disclosed |
| CN-108368083-B | Heteroaryl compounds and their use as therapeutic agents | 东亚首希控股股份有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20210317128-A1 | NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-14 | — | — | US | disclosed |
| US-20210317128-A1 | NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-14 | — | — | US | disclosed |
| US-20170066742-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO LTD (KR) | 2017-03-09 | — | — | US | disclosed |
| US-20170022167-A1 | OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2017-01-26 | — | — | US | disclosed |
| US-20170022167-A1 | OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2017-01-26 | — | — | US | disclosed |
| EP-3074379-A1 | OPIOID AGONISTS AND USES THEREOF | Nektar Therapeutics (India) Pvt. Ltd. (IN) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015079459-A1 | OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS (INDIA) PVT.LTD. (IN) | 2015-06-04 | — | — | WO | disclosed |
| WO-2005037828-A1 | NOVEL INHIBITORS OF DPP-IV, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES LTD. (KR) | 2005-04-28 | — | — | WO | disclosed |
| US-5811432-A | Azaoxindole derivatives | PFIZER INC (US) | 1998-09-22 | — | — | US | disclosed |
| CN-1031053-C | Azaoxindole derivatives | PFIZER (US) | 1996-02-21 | — | — | CN | disclosed |
| CN-1053065-A | AZAOXINDOLE DERIVATIVES | PFIZER (US) | 1991-07-17 | — | — | CN | disclosed |
| EP-0436333-A2 | Azaoxindole derivatives | PFIZER INC. (US) | 1991-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022167-A1 | OPIOID AGONISTS AND USES THEREOF | OPRM1, OPRK1, OPRD1 | KDM4E 3977/4885POLB 3777/4885TSHR 608/4885 |
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | KDM4E 1727/4885POLB 4707/4885TSHR 1878/4885 |
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | KDM4E 1727/4885POLB 4707/4885TSHR 1878/4885 |
| US-11319324-B2 | Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors | P2RX3, P2RX1, P2RX5 | KDM4E 3924/4885POLB 2313/4885TSHR 2897/4885 |
| US-20210317128-A1 | NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX1, P2RX5 | KDM4E 3993/4885POLB 1708/4885TSHR 3113/4885 |
| US-20170066742-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | KDM4E 1727/4885POLB 4707/4885TSHR 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.